Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

Strong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target 

Cash flow positive for the first nine months of 2024; $130 million generated in milestone and upfront payments to-date 

Read more at prnewswire.com